Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma
Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...
Ajay Nooka: Belantamab Mafodotin in Relapsed/Refractory Myeloma
Ajay K. Nooka, MD, shares safety and efficacy data from the phase II DREAMM-6 trial.
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis
Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...
Abby Statler: Are Clinical Trials Exclusion Criteria for AML Too Strict?
Abby Statler, PhD, MPH, discusses findings from an analysis of common clinical trial exclusion criteria and outcomes in clinical trials, which suggest that eligibility...
James Foran: Does Decitabine Maintenance Improve Survival in Older Patients With AML?
James M. Foran, MD, shares “compelling, but not definitive” results that appear to support the use of maintenance therapy with decitabine in older adults...
Saad Usmani: Adding Daratumumab to Carfilzomib + Dexamethasone Extends PFS
Saad Usmani, MD, MBBS, shares findings from the CANDOR trial, in which the three-drug combination reduced the risk of disease progression or death by...
Current Issue
November 2020 Bonus ASH Annual Meeting Preview Edition (Volume 6, Issue...
View issue flipbook
November 2020 Bonus ASH Annual Meeting Preview Edition
Volume 6, Issue 14This issue offers a behind-the-scenes look at this year's virtual annual meeting,...